Syros Pharmaceuticals is developing treatment options for patients with hematologic malignancies. Diseases arise when genes are expressed at the wrong time or in the wrong amount. Syros is developing small molecule medicines to control gene expression to provide treatment options for patients that currently have ineffective options. Their lead program is tamibarotene, SY-1425, an oral selective retinoid acid receptor alpha agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia. In addition, Syros is pursuing other targets for patients with various cancers.

Syros Pharmaceuticals

Founded: 2013
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin3
Therapy area: Higher-risk myelodysplastic syndrome
Drug types: ONC
Lead product: Tamibarotene
Funding: $130M stock Sep 2022; $90.5M stock Dec 2020

Drug notes:

About:

Jobs: